Coger: Distributeur de reactifs de laboratoire
AVANTI POLAR LIPIDS , CYGNUS , LARODAN , ADIPOGEN , MYBIOSOURCE , SERVA NORDMARK, BIOWORLD, EDGEBIO , PANREAC APPLICHEM
|
Ajouter au panier
Le produit a été ajouté au panier Le stock est insuffisant. unités ont été rajoutées au panier Total:
|
|
Stock épuisé.
En rupture de stock
|
|
Quantité minimum d'achat
La quantité minimum d'achat n'est pas atteinte
|
VX-745
50 mg
photos non contractuelles
Détails Produit
Product description: VX-745 is a potent inhibitor of p38alpha MAPK (IC50=10nM) with 20-fold selectivity over p38beta and 1000-fold selectivity over closely related kinases, ERK1, MK2 and JNK1-3. p38alpha is a member of the mitogen-activated protein kinase (MAPK) family of serine/threonine protein kinases and is widely expressed in endothelial, immune or inflammatory cells and plays a central role in the regulation of proinflammatory cytokine production including TNF-alpha, IL-1beta and IL-6. VX-745 is an anti-inflammatory agent that blocks IL-1beta and TNF-alpha release in whole blood in vitro with IC50 values of 150 and 180nM, respectively. VX-745 showed anti-inflammatory efficacy in an animal model of rheumatoid arthritis and recently anti-neuroinflammatory potential in prevention of early-stage Alzheimers diseases (AD).
Alternate Names/Synonyms: 5-(2,6-Dichlorophenyl)-2-(2,4-difluorophenylthio)-6H-pyrimido[1,6-b]pyridazin-6-one; Neflamapimod; VX745
CAS: 209410-46-8
|
Alerte
Veuillez saisir les champs obligatoires! |
